EP Patent

EP0297580B1 — Amorphous form of aztreonam

Assigned to ER Squibb and Sons LLC · Expires 1999-01-20 · 27y expired

What this patent protects

The non-crystalline, amorphous form of [3S-[3 alpha (Z),4 beta ]]-3[[2-amino-4-thiazolyl[1-carboxy-1-methylethoxy)imino]acetyl]ami no]-4-methyl-2-oxo-1-azetidinesulfonic acid and its pharmaceutically acceptable salts is prepared.

USPTO Abstract

The non-crystalline, amorphous form of [3S-[3 alpha (Z),4 beta ]]-3[[2-amino-4-thiazolyl[1-carboxy-1-methylethoxy)imino]acetyl]ami no]-4-methyl-2-oxo-1-azetidinesulfonic acid and its pharmaceutically acceptable salts is prepared.

Drugs covered by this patent

Patent Metadata

Patent number
EP0297580B1
Jurisdiction
EP
Classification
—
Expires
1999-01-20
Drug substance claim
No
Drug product claim
No
Assignee
ER Squibb and Sons LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.